long intergenic non-protein coding RNA 2192Genealiases: []
Q-omics provides the consensus-scored LINC02192 profile across patient tissues and cancer cell-line models. LINC02192 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02192 is differentially expressed in 6, with the highest sampling consensus in HNSC. Additionally, LINC02192 RNA expression shows 6,772 significant pathway-activity associations, with the highest sampling consensus in STAD. Together, these results highlight BRCA, HNSC, and STAD as cancer lineages where LINC02192 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02192 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02192 survival associations across molecular data types. LINC02192 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02192 RNA expression–survival associations across cancer types. High LINC02192 expression shows unfavorable associations in BRCA, HNSC, ACC and UCEC, but favorable associations in PAAD and MESO. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .012). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02192 RNA expression.
This table summarizes LINC02192 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 6. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02192. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02192 shows lower tumor expression in KIRC, KICH, PAAD and KIRP and higher tumor expression in HNSC and LUAD. The HNSC box plot shows higher LINC02192 RNA expression in tumor versus normal tissue (log2 FC = +0.045, t-test p = .009).
This table shows molecular features associated with LINC02192 in patient tissues and cancer cell lines. In patient samples, LINC02192 shows the broadest associations at the RNA and protein expression levels, with STAD recurring as the lineage with the largest associated feature set.
